Prof. Dr.  

Diamant Thaçi

, Lubeck - Germany

Presentations

Long-term Real-World Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: 10-Year Interim Results from the ESPRIT Registry 10 October 2019 08:40 - 08:50
A Phase II clinical trial of safety and efficacy of rVA576(Coversin) in adult mild to moderate bullous pemphigoid patients, first results of the pilot study 10 October 2019 16:00 - 16:10
Direct Comparison of Risankizumab and Fumaric Acid Esters (FAEs) in Patients with Moderate-to-Severe Plaque Psoriasis Who Were Naive to Systemic Therapy 11 October 2019 10:15 - 10:25
Dupilumab treatment for atopic dermatitis in Germany - patient characteristics, treatment history and disease severity in routine care 09 October 2019 00:00 - 00:00
An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study 09 October 2019 00:00 - 00:00
Efficacy of tildrakizumab in patients with moderate-to-severe psoriasis according to disease duration: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials at week 28 09 October 2019 00:00 - 00:00

Abstracts

An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study Psoriasis More
Dupilumab treatment for atopic dermatitis in Germany - patient characteristics, treatment history and disease severity in routine care Atopic Dermatitis/Eczema More
Efficacy of tildrakizumab in patients with moderate-to-severe psoriasis according to disease duration: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials at week 28 Psoriasis More
Direct Comparison of Risankizumab and Fumaric Acid Esters (FAEs) in Patients with Moderate-to-Severe Plaque Psoriasis Who Were Naive to Systemic Therapy Psoriasis More